immuron LIMITED

PRESS RELEASE: 7 April 2017

Immuron Appoints New Director – Prof. Ravi Savarirayan

Immuron Appoints New Director – Prof. Ravi Savarirayan

7 April 2017, Melbourne, Australia: Australian biopharmaceutical company Immuron Limited (ASX: IMC), is pleased to announce the appointment of Prof. Ravi Savarirayan to serve as a Director of the Company.

Ravi is a consultant clinical geneticist at the Victorian Clinical Genetics Services, as well as Professor and Research Group Leader (Skeletal Biology and Disease) at the Murdoch Childrens Research Institute. Ravi received his MBBS from the University of Adelaide in 1990 and became a fellow of the Royal Australasian College of Physicians in 1997. He was certified as a specialist in clinical genetics from the Human Genetics Society of Australasia in 1998 and received his Doctor of Medicine from the University of Melbourne in 2004, for his thesis "Clinical and molecular studies in the osteochondrodysplasias."

He is a founding member of the Skeletal Dysplasia Management Consortium and has been the Chair of the Specialist Advisory Committee in Clinical Genetics, Royal Australasian College of Physicians since 2009. He was president of the International Skeletal Dysplasia Society from 2009 to 2011 and has been an invited member of several International Working Committees on Constitutional Diseases of Bone. Ravi's primary research focus is on inherited disorders of the skeleton causing short stature, arthritis and osteoporosis. He has published over 150 peer-reviewed articles, collaborating with peers from over 30 countries, and is on the editorial board of Human Mutation, European Journal of Human Genetics, American Journal of Medical Genetics and Journal of Medical Genetics.

Professor Savarirayan is committed to bringing innovative treatments to patients, and is the Lead investigator of Phase 2 and 3 international clinical trials aimed at treating children with dwarfism with a new precision therapy.

Immuron Chairman Dr. Roger Aston welcomed Prof. Savarirayan's appointment to the Board saying:

> *"Prof. Savarirayan's clinical and regulatory experience will be pivotal as Immuron Limited continues to strengthen its position in the on-going NASH clinical trial.*

ABN: 80 063 114 045
Suite 1, 1233 High Street, Armadale, Victoria AUSTRALIA 3143
www.immuron.com | **Phone:** + 61 (0)3 9824 5254 | **Facsimile:** + 61 (0)3 9822 7735

COMPANY CONTACT:
Thomas Liquard

Chief Executive Officer
Ph: +61 (0)3 9824 5254
thomasliquard@immuron.com

ABOUT IMMURON:

Immuron Ltd (ASX: IMC; OTCQB: IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers' diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company's other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market. For more information visit: **http://www.immuron.com**

FORWARD-LOOKING STATEMENTS:

Certain statements made in this release are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.